NeuropsychiatrieHK s.r.o.
- Address
- lock Available on a paid plan
Immune System Diseases
The research team at NeuropsychiatrieHK s.r.o. focuses on strengthening immune defenses in patients with compromised antibody production. Studies aim to reduce infection risk in individuals with hypogammaglobulinemia and those receiving B‑cell depletion therapy.
- Prevention of major infections in hypogammaglobulinemia
- Safety of immunoglobulin replacement during autoimmune treatment
- Evaluation of infection‑preventive biologics
- Support of immune function in rheumatic conditions
Findings from these trials could improve prophylactic strategies and enhance quality of life for patients undergoing immune‑modulating therapies.
Nervous System Diseases
In the field of neurology, the site investigates headache disorders and dementia‑related agitation. Current work evaluates the impact of Dysport and IPN10200 on reducing headache frequency, as well as the potential of EXV‑802 to calm agitation in Alzheimer’s disease dementia.
- Chronic migraine prevention
- Episodic migraine management
- Agitation reduction in dementia
- Assessment of novel neuro‑therapeutics
These efforts aim to provide safer, more effective options for patients struggling with frequent migraines or behavioral symptoms of dementia.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Exciva GmbH1active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Ipsen Innovation2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in NeuropsychiatrieHK s.r.o.
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety Evaluation of Botulinum Toxin Type A in Chronic Migraine Prevention in Adults: A Randomized, Double-Blind, Placebo-Controlled Study | Ipsen Innovation | Phase III | Not Recruiting | Mar 2024 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Human Normal Immunoglobulin | 2 | Unknown | 2026-07-31 | 2026-07-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.